<p>Tiziana Life Sciences Ltd（納斯達克代碼：TLSA - 獲取免費報告）週四股價下跌 4.4%。該公司最低交易價格為 1.70 美元，最後交易價格為 1.72 美元。在午盤交易中，共成交 145,761 股，較平均交易量 249,876 股下降了 42%。該股票此前收盤價為 1.80 美元。</p>
<p>獲取 <strong>Tiziana Life Sciences</strong> 的提醒：</p>
<h2>分析師設定新的價格目標</h2>
<p>另外，Weiss Ratings 在 10 月 8 日的報告中重申了對 Tiziana Life Sciences 股票的 “賣出（d-）” 評級。一位研究分析師對該股票給予了賣出評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “賣出”。</p>
<p><strong>查看我們最新的 TLSA 股票分析</strong></p>
<h2>Tiziana Life Sciences 股票下跌 4.4%</h2>
<p>該公司的 50 日移動平均價格為 1.86 美元，200 日移動平均價格為 1.79 美元。</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金和其他機構投資者最近增加或減少了對該公司的持股。Millennium Management LLC 在第三季度購買了價值約 520,000 美元的 Tiziana Life Sciences 新股份。Jane Street Group LLC 在第一季度將其在 Tiziana Life Sciences 的持股增加了 968.2%。Jane Street Group LLC 目前擁有 167,542 股該公司的股票，價值 181,000 美元，此前在上一季度又購買了 151,858 股。OMERS ADMINISTRATION Corp 在第一季度收購了價值 156,000 美元的 Tiziana Life Sciences 新股份。Bison Wealth LLC 在第四季度購買了價值 30,000 美元的 Tiziana Life Sciences 新股份。最後，ARS Investment Partners LLC 在第三季度購買了價值 66,000 美元的 Tiziana Life Sciences 新股份。</p>
<h2>關於 Tiziana Life Sciences</h2>
<p>（獲取免費報告）</p>
<p>Tiziana Life Sciences Ltd 是一家生物技術公司，專注於發現和開發治療腫瘤學和免疫學人類疾病的分子。該公司在免疫學領域的主要產品候選藥物是 Foralumab（TZLS-401），這是一種人源性抗 CD3 單克隆抗體（mAb），用於治療克羅恩病、移植物抗宿主病、潰瘍性結腸炎、多發性硬化症、1 型糖尿病、炎症性腸病、銀屑病和類風濕關節炎等疾病。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Tiziana Life Sciences</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>2026 年應避免的三隻最近被下調評級的股票</li>
<li>如何計算退休收入：MarketBeat 的計算器</li>
<li>芯片熱潮迴歸：三隻有望大幅上漲的股票</li>
<li>內部人士賣出解釋：這能否影響你的投資選擇？</li>
<li>甲骨文股票遭重創：為何其 AI 管道可能推動 2026 年反彈</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Tiziana Life Sciences 嗎？</h2>
<p>在考慮 Tiziana Life Sciences 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Tiziana Life Sciences 並不在名單上。</p>
<p>雖然 Tiziana Life Sciences 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TLSA

<p>Tiziana Life Sciences (NASDAQ:TLSA) 的股價下跌了 4.4%，至 1.72 美元，交易量較平均水平下降了 42%。Weiss Ratings 重申了 “賣出” 評級，該股票的共識評級為 “賣出”。機構投資者已調整其持股，有些增加了持股，有些則減少了持股。Tiziana 專注於開發腫瘤學和免疫學領域的疾病治療方案。儘管當前的評級為 “賣出”，分析師建議其他股票作為更好的投資選擇</p>

<p>Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report)'s share price fell 4.4% on Thursday . The company traded as low as $1.70 and last traded at $1.72. 145,761 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 249,876 shares. The stock had previously closed at $1.80.</p>
<div class="lb-trans"><p>Tiziana Life Sciences Ltd（納斯達克代碼：TLSA - 獲取免費報告）週四股價下跌 4.4%。該公司最低交易價格為 1.70 美元，最後交易價格為 1.72 美元。在午盤交易中，共成交 145,761 股，較平均交易量 249,876 股下降了 42%。該股票此前收盤價為 1.80 美元。</p>
</div><p>Get <strong>Tiziana Life Sciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Tiziana Life Sciences</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>Separately, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Tiziana Life Sciences in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的報告中重申了對 Tiziana Life Sciences 股票的 “賣出（d-）” 評級。一位研究分析師對該股票給予了賣出評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “賣出”。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on TLSA</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 TLSA 股票分析</strong></p>
</div><h2>Tiziana Life Sciences Stock Down 4.4%</h2>
<div class="lb-trans"><h2>Tiziana Life Sciences 股票下跌 4.4%</h2>
</div><p>The business's 50 day moving average price is $1.86 and its 200-day moving average price is $1.79.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均價格為 1.86 美元，200 日移動平均價格為 1.79 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new stake in shares of Tiziana Life Sciences in the 3rd quarter valued at approximately $520,000. Jane Street Group LLC boosted its stake in Tiziana Life Sciences by 968.2% in the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock valued at $181,000 after buying an additional 151,858 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Tiziana Life Sciences in the 1st quarter valued at $156,000. Bison Wealth LLC bought a new stake in Tiziana Life Sciences in the fourth quarter valued at $30,000. Finally, ARS Investment Partners LLC bought a new stake in Tiziana Life Sciences in the third quarter valued at $66,000.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近增加或減少了對該公司的持股。Millennium Management LLC 在第三季度購買了價值約 520,000 美元的 Tiziana Life Sciences 新股份。Jane Street Group LLC 在第一季度將其在 Tiziana Life Sciences 的持股增加了 968.2%。Jane Street Group LLC 目前擁有 167,542 股該公司的股票，價值 181,000 美元，此前在上一季度又購買了 151,858 股。OMERS ADMINISTRATION Corp 在第一季度收購了價值 156,000 美元的 Tiziana Life Sciences 新股份。Bison Wealth LLC 在第四季度購買了價值 30,000 美元的 Tiziana Life Sciences 新股份。最後，ARS Investment Partners LLC 在第三季度購買了價值 66,000 美元的 Tiziana Life Sciences 新股份。</p>
</div><h2>About Tiziana Life Sciences</h2>
<div class="lb-trans"><h2>關於 Tiziana Life Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.</p>
<div class="lb-trans"><p>Tiziana Life Sciences Ltd 是一家生物技術公司，專注於發現和開發治療腫瘤學和免疫學人類疾病的分子。該公司在免疫學領域的主要產品候選藥物是 Foralumab（TZLS-401），這是一種人源性抗 CD3 單克隆抗體（mAb），用於治療克羅恩病、移植物抗宿主病、潰瘍性結腸炎、多發性硬化症、1 型糖尿病、炎症性腸病、銀屑病和類風濕關節炎等疾病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Tiziana Life Sciences</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Tiziana Life Sciences</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>2026 年應避免的三隻最近被下調評級的股票</li>
<li>如何計算退休收入：MarketBeat 的計算器</li>
<li>芯片熱潮迴歸：三隻有望大幅上漲的股票</li>
<li>內部人士賣出解釋：這能否影響你的投資選擇？</li>
<li>甲骨文股票遭重創：為何其 AI 管道可能推動 2026 年反彈</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tiziana Life Sciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Tiziana Life Sciences 嗎？</h2>
</div><p>Before you consider Tiziana Life Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Tiziana Life Sciences 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Tiziana Life Sciences 並不在名單上。</p>
</div><p>While Tiziana Life Sciences currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tiziana Life Sciences 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Tiziana Life Sciences（NASDAQ:TLSA）股價下跌 4.4% - 以下是原因